TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36370817

Group type: EXPERIMENTAL
Intervention: Higher recirculation air rates in fully occupied cabins
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Higher recirculation air rates in half-occupied cabins
Number of subjects: 559

Group type: COMPARATOR
Intervention: Full occupancy
Number of subjects: 559

Group type: COMPARATOR
Intervention: Half occupancy
Number of subjects: 559
Study: 33637882

Group type: EXPERIMENTAL
Intervention: Low-dose decitabine (DAC) 20 mg/m2/d, i.v. for 5 days followed by modified Busulfan-Cyclophosphamide (Bu-Cy)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Modified Busulfan-Cyclophosphamide (Bu-Cy) only
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Low-dose decitabine (DAC) 20 mg/m2/d, i.v. for 5 days followed by modified Busulfan-Cyclophosphamide (Bu-Cy) in patients with active disease
Number of subjects: 236

Group type: COMPARATOR
Intervention: Modified Busulfan-Cyclophosphamide (Bu-Cy) only in patients with active disease
Number of subjects: 236
Study: 35317785

Group type: EXPERIMENTAL
Intervention: New model of care employing general practitioners (GPs) in RACFs
Number of subjects: 0
Study: 34598692

Group type: EXPERIMENTAL
Intervention: HOP‐UP‐PT program (Home‐based Older Persons Upstreaming Prevention‐Physical Therapy) delivered by physical therapists over nine encounters (six in-person, three telerehabilitation) spanning seven months.
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: HOP‐UP‐PT program participants (EG)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group (CG) continued their usual physical activity routines during the same time frame.
Number of subjects: 144
Study: 32583295

Group type: EXPERIMENTAL
Intervention: Oliceridine 0.1 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Oliceridine 0.35 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Oliceridine 0.5 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Morphine 1 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Oliceridine (all doses)
Number of subjects: 100
Study: 35196591

Group type: EXPERIMENTAL
Intervention: 0.1% nepafenac eye drops, thrice daily for 2 weeks
Number of subjects: 160

Group type: COMPARATOR
Intervention: 0.09% bromfenac eye drops, twice daily for 2 weeks
Number of subjects: 160
Study: 33823927

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS) over the bilateral tempo-parietal junction at 2.0 mA for 10 days, combined with computer-based cognitive training.
Number of subjects: 0
Study: 34020928

Group type: EXPERIMENTAL
Intervention: PASCAL transcatheter valve repair system
Number of subjects: 124
Study: 33902584

Group type: EXPERIMENTAL
Intervention: Nintedanib 150 mg twice daily
Number of subjects: 1690

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1690
Study: 32112591

Group type: EXPERIMENTAL
Intervention: Intralesional 5‐fluorouracil (5‐FU) injections
Number of subjects: 43

Group type: COMPARATOR
Intervention: Intralesional triamcinolone (TAC) injections
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Both 5‐FU and TAC injections
Number of subjects: 43
Study: 32371116

Group type: EXPERIMENTAL
Intervention: CADe system (GI‐Genius, Medtronic) during high‐definition colonoscopies
Number of subjects: 685

Group type: COMPARATOR
Intervention: Control group (no CADe system) during high‐definition colonoscopies
Number of subjects: 685
Study: 35902633

Group type: EXPERIMENTAL
Intervention: Random Forest (RF) machine learning algorithm
Number of subjects: 12747
Study: 33596848

Group type: EXPERIMENTAL
Intervention: Refined ultra-short regimen guided by molecular DST to pyrazinamide via whole-genome sequencing (WGS) for 24-32 weeks (pyrazinamide-susceptible) or 36-44 weeks (pyrazinamide-resistant)
Number of subjects: 354

Group type: COMPARATOR
Intervention: WHO injectable-containing shorter regimen for 36-44 weeks depending on time of sputum smear conversion
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Refined ultra-short regimen
Number of subjects: 354
Study: 32019783

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 34587650

Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice (NO3, 9 mmol)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 8
Study: 35606868

Group type: EXPERIMENTAL
Intervention: 1-day e-learning educational programme on perinatal psychological issues
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 115
Study: 33048267

Group type: EXPERIMENTAL
Intervention: Negative Life Events (NLEs) in the academic domain
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Failed a grade in school
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Negative change in acceptance by peers
Number of subjects: 319
Study: 32554878

Group type: EXPERIMENTAL
Intervention: Polyphenols
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Pyrogallic acid
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Polyphenols concentration
Number of subjects: 16
Study: 34398703

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Study skills active control
Number of subjects: 85

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 85
Study: 33487513

Group type: EXPERIMENTAL
Intervention: (R/S)-ketamine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: (S)-ketamine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 32352353

Group type: EXPERIMENTAL
Intervention: 0.1% EGCG dentin pretreatment + etch-and-rinse
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 0.1% EGCG dentin pretreatment + self-etch
Number of subjects: 33

Group type: COMPARATOR
Intervention: etch-and-rinse
Number of subjects: 33

Group type: COMPARATOR
Intervention: self-etch
Number of subjects: 33
Study: 35228305

Group type: EXPERIMENTAL
Intervention: NAVA
Number of subjects: 26

Group type: COMPARATOR
Intervention: Variable PSV
Number of subjects: 26
Study: 35690253

Group type: EXPERIMENTAL
Intervention: BAND
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: BRACE
Number of subjects: 30

Group type: COMPARATOR
Intervention: CONTROL
Number of subjects: 30
Study: 32469388

Group type: EXPERIMENTAL
Intervention: HIGH protein diet (1.6 g protein/kg/d)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: LOW protein diet (0.5 g protein/kg/d)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: NO protein diet (0.15 g protein/kg/d)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: D2O ingestion
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Daily MyoPS rates during immobilization
Number of subjects: 33
Study: 32732142

Group type: EXPERIMENTAL
Intervention: Inactivated quadrivalent influenza vaccine (IIV4)
Number of subjects: 2320

Group type: COMPARATOR
Intervention: Inactivated trivalent influenza vaccine (IIV3-BV)
Number of subjects: 2320

Group type: COMPARATOR
Intervention: Inactivated trivalent influenza vaccine (IIV3-BY)
Number of subjects: 2320
Study: 34118255

Group type: EXPERIMENTAL
Intervention: Preparation up to size 25.04
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Preparation up to size 25.06
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Preparation up to size 30.04
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Preparation up to size 30.06
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (no preparation in the MM canal)
Number of subjects: 55
Study: 32947474

Group type: EXPERIMENTAL
Intervention: Antithrombin supplementation (treatment group)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (no antithrombin supplementation)
Number of subjects: 48
Study: 34931346

Group type: EXPERIMENTAL
Intervention: Ixekizumab treatment
Number of subjects: 0
Study: 34605666

Group type: EXPERIMENTAL
Intervention: Metacognition+TM intervention (an hourlong workshop on effective learning strategies and self-awareness plus a second hourlong workshop on time management and procrastination)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Baseline Metacognition intervention (an hourlong workshop focused on effective learning strategies and self-awareness)
Number of subjects: 17
Study: 32160632

Group type: COMPARATOR
Intervention: Universal iodine supplementation (control group)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Targeted iodine supplementation (study group)
Number of subjects: 208
Study: 35832418

Group type: EXPERIMENTAL
Intervention: ZOL + ELD
Number of subjects: 98

Group type: COMPARATOR
Intervention: ZOL
Number of subjects: 98
Study: 32187610

Group type: EXPERIMENTAL
Intervention: French version of The Whiplash Book
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no training or information)
Number of subjects: 0
Study: 36030839

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 89
Study: 34621054

Group type: EXPERIMENTAL
Intervention: PGT121 at 3, 10 and 30 mg kg-1
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: PGT121 at 30 mg kg-1
Number of subjects: 48
Study: 32965230

Group type: EXPERIMENTAL
Intervention: Tailored mHealth intervention
Number of subjects: 42

Group type: COMPARATOR
Intervention: Attention control (AC)
Number of subjects: 42
Study: 33731364

Group type: EXPERIMENTAL
Intervention: DIMS lenses (n=65)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control-to-DIMS group (n=55)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: DIMS lenses vs historical control
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control-to-DIMS vs historical control
Number of subjects: 128
Study: 33337436

Group type: EXPERIMENTAL
Intervention: Standard duration varenicline
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Extended duration varenicline
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Quitters
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 32985421

Group type: EXPERIMENTAL
Intervention: Out-of-pocket health expenditure (OOPE)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Catastrophic health expenditure (CHE)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Type of village (presence of public health-care facility)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Presence of health insurance
Number of subjects: 235

Group type: COMPARATOR
Intervention: Gender of the head of the family
Number of subjects: 235
Study: 35267206

Group type: EXPERIMENTAL
Intervention: Mailed nicotine replacement therapy (NRT) and Quitline support
Number of subjects: 748

Group type: COMPARATOR
Intervention: Control group (normal care)
Number of subjects: 748

Group type: EXPERIMENTAL
Intervention: Intervention group (those who quit before surgery)
Number of subjects: 748

Group type: COMPARATOR
Intervention: Control group (those who quit before surgery)
Number of subjects: 748
Study: 33302926

Group type: EXPERIMENTAL
Intervention: Contoured foot orthoses
Number of subjects: 88

Group type: COMPARATOR
Intervention: Sham flat insoles
Number of subjects: 88
Study: 34117385

Group type: EXPERIMENTAL
Intervention: Transconjunctival (Tconj) local anaesthetic administration
Number of subjects: 30

Group type: COMPARATOR
Intervention: Transcutaneous (Tskin) local anaesthetic administration
Number of subjects: 30
Study: 34580055

Group type: EXPERIMENTAL
Intervention: Fiasp plus pramlintide fully closed-loop system
Number of subjects: 28

Group type: COMPARATOR
Intervention: Fiasp-alone hybrid closed-loop system
Number of subjects: 28
Study: 36265196

Group type: EXPERIMENTAL
Intervention: 10‐Hz rTMS
Number of subjects: 64

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 64
Study: 34542060

Group type: EXPERIMENTAL
Intervention: Sustained Natural Apophyseal Glides (SNAGs)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 40
Study: 35536699

Group type: EXPERIMENTAL
Intervention: Prior contextual information about the trolley problem
Number of subjects: 119

Group type: COMPARATOR
Intervention: No prior contextual information about the trolley problem
Number of subjects: 119
Study: 34132192

Group type: EXPERIMENTAL
Intervention: ranibizumab
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: aflibercept
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: bevacizumab
Number of subjects: 463
Study: 36031810

Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 6635

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6635
Study: 34412057

Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILI)
Number of subjects: 3938

Group type: COMPARATOR
Intervention: Diabetes Support and Education (DSE)
Number of subjects: 3938
Study: 34088513

Group type: COMPARATOR
Intervention: Oral metronomic therapy with etoposide (50 mg, day 1 to 14) and cyclophosphamide (50 mg, day 1 to 28, every 4 weeks)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Pazopanib (400 mg once daily) in addition to etoposide and cyclophosphamide
Number of subjects: 75

Group type: COMPARATOR
Intervention: Oral metronomic therapy with etoposide and cyclophosphamide
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Pazopanib in addition to etoposide and cyclophosphamide
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Quality of life (QoL) assessment in Arm B
Number of subjects: 75

Group type: COMPARATOR
Intervention: Serum VEGF and PDGF levels in both arms
Number of subjects: 75
Study: 32766862

Group type: EXPERIMENTAL
Intervention: Direct to consumer referral pathway (e.g., digital and print media, registry emails)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Provider referral pathway (i.e., electronic health record [EHR] order and provider recommendation)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Other referral approaches (e.g., presentations, word of mouth)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Overall referral pathways
Number of subjects: 313
Study: 33559816

Group type: EXPERIMENTAL
Intervention: Solution-oriented counseling
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study: 32389457

Group type: EXPERIMENTAL
Intervention: Self-injected subcutaneous depot medroxyprogesterone acetate (DMPA-SC)
Number of subjects: 731

Group type: EXPERIMENTAL
Intervention: Provider-administered subcutaneous depot medroxyprogesterone acetate (DMPA-SC)
Number of subjects: 731

Group type: EXPERIMENTAL
Intervention: Self-injected and provider-administered subcutaneous depot medroxyprogesterone acetate (DMPA-SC)
Number of subjects: 731
Study: 36178914

Group type: EXPERIMENTAL
Intervention: Traditional foods index (measured as weekly servings of traditional food consumption divided by total foods reported)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Traditional foods index during summer
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Traditional foods index during winter
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Traditional foods index by gender (women)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Traditional foods index by gender (men)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Traditional foods index by community size (smaller communities)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Traditional foods index by community size (larger community of Nome)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Correlation with age
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Correlation with community connectedness
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Correlation with community standing
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Correlation with traditional language comprehension
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Multivariate regression model
Number of subjects: 291
Study: 34293213

Group type: EXPERIMENTAL
Intervention: Higher genetic risk score (GRS) for IGF‐1
Number of subjects: 2011

Group type: EXPERIMENTAL
Intervention: Summary statistics‐based MR method, inverse‐variance weighting (IVW)
Number of subjects: 2011

Group type: COMPARATOR
Intervention: High GRS group (compared to low GRS group)
Number of subjects: 2011
Study: 33318391

Group type: EXPERIMENTAL
Intervention: Daily salt intake estimated using the INTERSALT equation from morning spot urine samples.
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Waist circumference measurement.
Number of subjects: 426
Study: 35079838

Group type: EXPERIMENTAL
Intervention: PRESIONA (therapeutic exercise and blood flow restriction program)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 80
Study: 33338232

Group type: EXPERIMENTAL
Intervention: Sofosbuvir/daclatasvir plus hydroxychloroquine
Number of subjects: 55

Group type: COMPARATOR
Intervention: Hydroxychloroquine alone
Number of subjects: 55
Study: 34553480

Group type: EXPERIMENTAL
Intervention: Individualised, targeted step count intervention and usual care
Number of subjects: 96

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 96
Study: 32686116

Group type: EXPERIMENTAL
Intervention: reminder + FIT
Number of subjects: 35000

Group type: COMPARATOR
Intervention: reminder-only
Number of subjects: 35000
Study: 33892170

Group type: EXPERIMENTAL
Intervention: Intervention group received glaucoma education, personalized disease management suggestions, and a reminder aid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group received education regarding general eye health
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 0
Study: 33231866

Group type: EXPERIMENTAL
Intervention: Gemcitabine (1000 mg/m2 on days 1 and 8) + Pazopanib (800 mg daily)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Gemcitabine (900 mg/m2 on days 1 and 8) + Docetaxel (100 mg/m2 on day 8)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Gemcitabine + Docetaxel
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Gemcitabine + Pazopanib
Number of subjects: 90
Study: 34789450

Group type: EXPERIMENTAL
Intervention: CAL-assisted PDT (calcipotriol applied daily for 15 days beforehand)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional PDT
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CAL-assisted PDT
Number of subjects: 20
Study: 33164226

Group type: EXPERIMENTAL
Intervention: Renewed consistent practice for pressure ulcer prevention based on international guidelines.
Number of subjects: 141
Study: 36031694

Group type: EXPERIMENTAL
Intervention: Hippotherapy simulation exercise
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional home exercises
Number of subjects: 40
Study: 33432646

Group type: EXPERIMENTAL
Intervention: KgDRL (knowledge-guided deep reinforcement learning)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Standard DRL (deep reinforcement learning)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Rule-based treatment planning
Number of subjects: 74
Study: 33357218

Group type: EXPERIMENTAL
Intervention: Transverse uterine incision
Number of subjects: 52

Group type: COMPARATOR
Intervention: Longitudinal uterine incision
Number of subjects: 52
Study: 34653732

Group type: EXPERIMENTAL
Intervention: Nanocurcumin (80 mg capsule daily for 8 weeks)
Number of subjects: 36
Study: 32579483

Group type: EXPERIMENTAL
Intervention: Combined (dexmedetomidine + epidural blockade)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control (0.9% saline)
Number of subjects: 96
Study: 32883337

Group type: EXPERIMENTAL
Intervention: Strength-based case management (SBCM-ED) with a maximum of six case management sessions within 90 days of enrollment
Number of subjects: 300

Group type: COMPARATOR
Intervention: Screening, assessment, and referral alone (SAR)
Number of subjects: 300
Study: 35302529

Group type: EXPERIMENTAL
Intervention: Motor imagery + action observation therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cognitive training
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Mixed therapy (cognitive training + motor imagery + action observation therapy)
Number of subjects: 30
Study: 36262507

Group type: EXPERIMENTAL
Intervention: 200mg of simethicone (Group A)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo (Group B)
Number of subjects: 99
Study: 34374847

Group type: EXPERIMENTAL
Intervention: Hypnosis-derived communication (HC) administered by trained nurses during outpatient chemotherapy.
Number of subjects: 49

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 49
Study: 36197257

Group type: EXPERIMENTAL
Intervention: Printed education materials plus personal education
Number of subjects: 61

Group type: COMPARATOR
Intervention: Printed education materials only (Control)
Number of subjects: 61
Study: 33199422

Group type: EXPERIMENTAL
Intervention: Sodium selenate (15 mg three times a day)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 35697435

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBGT)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 75
Study: 34393186

Group type: EXPERIMENTAL
Intervention: Gastric Bypass (GB)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sleeve Gastrectomy (SG)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Gastric Bypass (GB) - Noncomplete Remitters
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sleeve Gastrectomy (SG) - Nonremitters
Number of subjects: 60
Study: 35589674

Group type: EXPERIMENTAL
Intervention: Combined paracetamol-dexamethasone
Number of subjects: 100

Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 100
Study: 34226220

Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery (CRS)
Number of subjects: 0
Study: 34375855

Group type: EXPERIMENTAL
Intervention: Exercise therapy with booster sessions
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Exercise therapy plus manual therapy
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Exercise therapy plus manual therapy with booster sessions
Number of subjects: 75

Group type: COMPARATOR
Intervention: Exercise therapy (control group)
Number of subjects: 75
Study: 35338648

Group type: EXPERIMENTAL
Intervention: Restricted IV fluid therapy
Number of subjects: 1554

Group type: COMPARATOR
Intervention: Standard IV fluid therapy
Number of subjects: 1554
Study: 33200899

Group type: COMPARATOR
Intervention: Laparoscopic simple prostatectomy (LSP)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Robot-assisted simple prostatectomy (RASP)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Holmium laser enucleation of prostate (HoLEP)
Number of subjects: 110
Study: 32599641

Group type: EXPERIMENTAL
Intervention: High-intensity training program
Number of subjects: 23

Group type: COMPARATOR
Intervention: Moderate-intensity training program
Number of subjects: 23